arrow
L

Lydia Scarfò

università vita-salute san raffaele
H指数:43
被引数:6,653

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Correction: Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study

更正:携带t(14;19)易位的慢性淋巴细胞白血病患者临床和转录组学特征:一项ERIC研究

Leukemia
IF13.4
2026-10-160
OAAI
Integrated multi-omic profiling reveals two distinct splenic marginal zone lymphoma subgroups with prognostic relevance

整合多组学分析揭示两种具有预后意义的脾边缘区淋巴瘤亚群

2026-05-280
OAAI
Molecular and functional characterization of the B-cell receptor in chronic lymphocytic leukemia-like monoclonal B-cell lymphocytosis

B细胞受体在慢性淋巴细胞白血病样单克隆B细胞淋巴增生病中的分子和功能表征

Leukemia
IF13.4
2026-01-070
OAAI
Fixed-Duration versus Continuous Treatment for Chronic Lymphocytic Leukemia

Al-Sawaf, O.; Stumpf, J.; Zhang, C.; Simon, F.; Bosch, F.; Feyzi, E.; Ghia, P.; Gregor, M.; Kater, A.P.; Lindström, V.; 等. 固定疗程与持续治疗在慢性淋巴细胞白血病中的应用比较. N. Engl. J. Med. 2025, 393, 24. [Google Scholar] [CrossRef]

2025-12-018
PRE
Central Nervous System Involvement in CLL: An International Retrospective Study by ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病中中枢神经系统受累:ERIC(欧洲慢性淋巴细胞白血病研究倡议)国际回顾性研究

2025-10-280
OAAI
CD19 CAR T-Cell Therapy in Richter Transformation: A Multicentre Retrospective Analysis by the European Research Initiative on Chronic Lymphocytic Leukaemia

CD19 CAR T细胞疗法在Richter转化中的研究:欧洲慢性淋巴细胞白血病研究倡议进行的 multicentre 回顾性分析

2025-10-220
OAAI
Clinical and transcriptomic characterization of patients with chronic lymphocytic leukemia harboring t(14;19): an ERIC study

携带t(14;19)易位的慢性淋巴细胞白血病患者临床及转录组学特征:一项ERIC研究

Leukemia
IF13.4
2025-09-190
OAAI
Disease-specific U1 spliceosomal RNA mutations in mature B-cell neoplasms

特定疾病的U1剪接体RNA突变在成熟B细胞肿瘤中

Leukemia
IF13.4
2025-06-300
OAAI
Resistance to targeted therapies in chronic lymphocytic leukemia: Current status and perspectives for clinical and diagnostic practice

慢性淋巴细胞白血病对靶向疗法的耐药性:临床和诊断实践中的现状与展望

Leukemia
IF13.4
2025-06-240
OAAI
Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort

基于维奈克拉茨方案的八旬慢性淋巴细胞白血病患者:疗效、安全性及与BTKi的比较(多中心队列研究)

2025-04-240
OA
Bcor loss promotes Richter transformation of chronic lymphocytic leukemia associated with Notch1 activation in mice

Bcor基因缺失促进与Notch1激活相关的慢性淋巴细胞白血病向Richter转化的发生(小鼠模型)。

LEUKEMIA
IF13.4
2025-03-200
OA
Acalabrutinib in High-Risk Chronic Lymphocytic Leukaemia Naïve Patients: An Italian Multicenter Retrospective Observational Real-Life Experience
2025-01-140
OAAI
Kinetics of lymphocytosis in naïve chronic lymphocytic leukemia patients treated with covalent Bruton's tyrosine kinase inhibitors: An Italian multicenter real-life experience
2024-11-280
OAAI
Baseline Characteristics from Arise Study, an Italian Non-Interventional Study Assessing the Real-World Use of Acalabrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

来自Arise研究(一项评估阿卡替尼在慢性淋巴细胞白血病(CLL)患者真实世界治疗中应用的意大利非干预性研究)的基线特征

BLOOD
IF23.1
2024-11-050
PRE
Therapeutic strategies and treatment sequencing in patients with chronic lymphocytic leukemia: An international study of ERIC, the European Research Initiative on CLL

慢性淋巴细胞白血病患者的治疗策略和治疗顺序: 欧洲CLL研究计划ERIC的国际研究

2024-09-170
OAAI